Swiss-based immunology company Granite Bio has secured $100m in funding for its new antibody treatments that target several ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

Swiss-American biotech Granite Bio has exited stealth mode with $100 million in funding and plans to advance two experimental ...

Based in Basel, Granite Bio has emerged from stealth with a focus on developing first-in-class antibodies targeting multiple autoimmune diseases. The company has secured $100 million in two funding ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing antibodies in autoimmune diseases and allergies. The financing round was ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Children born to anti-Ro antibody-positive mothers do not exhibit a greater prevalence of allergic, neurodevelopmental, or autoimmune conditions.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...